儿童横纹肌肉瘤间变型的预后意义:儿童肿瘤协作组报告
本研究纳入五项儿童肿瘤协作组横纹肌肉瘤临床试验中经中心病理复审的患者(D9602 n=357;D9802 n=80;D9803 n=462;ARST0331 n=335;ARST0531 n=414),评估间变型与总生存(OS)及无失败生存(FFS)的关系。多因素分析显示间变型并非独立预后因素(OS:HR=1.12,p=0.43;FFS:HR=1.07,p=0.56);在TP53突变肿瘤中69%伴间变型,而间变型肿瘤中仅24%伴TP53突变。
要点
- 间变型在胚胎型横纹肌肉瘤中更常见(27%),其他亚型为7%–11%。
- 多因素分析中间变型不是横纹肌肉瘤的独立预后因素。
- 间变型可能是部分病例TP53突变的替代标志,值得进一步研究。
核心结论
- 间变型不是横纹肌肉瘤不良结局的独立预后指标。
- TP53突变与间变型存在关联,间变型可能是部分病例TP53突变的替代标志。
- 肿瘤TP53突变状态可作为未来研究的预后指标方向。
研究设计与样本
- 研究纳入五项儿童肿瘤协作组横纹肌肉瘤临床试验中经前瞻性中心病理复审的患者。
- 试验及样本量:D9602 n=357;D9802 n=80;D9803 n=462;ARST0331 n=335;ARST0531 n=414。
- 记录人口学信息、危险组、组织学亚型、间变型及OS和FFS,FFS失败定义为复发、进展或死亡。
- 采用log-rank检验比较OS和FFS。
主要发现
- 间变型在胚胎型横纹肌肉瘤中占27%,高于肺泡型11%、葡萄状型7%、梭形细胞型11%。
- 全部亚型多因素分析:间变型对OS的HR=1.12(p=0.43),对FFS的HR=1.07(p=0.56)。
- 仅在胚胎型横纹肌肉瘤中多因素分析:间变型对OS的HR=1.41(p=0.078),对FFS的HR=1.25(p=0.16)。
- TP53突变肿瘤中69%伴间变型,间变型肿瘤中仅24%伴肿瘤TP53突变。
关键数值与推荐
- 间变型在胚胎型横纹肌肉瘤中占27%,肺泡型11%,葡萄状型7%,梭形细胞型11%。
- 全部亚型多因素分析:OS的HR=1.12(p=0.43),FFS的HR=1.07(p=0.56)。
- 胚胎型横纹肌肉瘤多因素分析:OS的HR=1.41(p=0.078),FFS的HR=1.25(p=0.16)。
- TP53突变肿瘤中69%有间变型;间变型肿瘤中24%有肿瘤TP53突变。
临床怎么用
- 儿童横纹肌肉瘤病理报告中间变型不应单独作为不良预后分层依据。
- 对间变型病例可考虑结合TP53突变状态评估预后,但需未来研究验证。
- 胚胎型横纹肌肉瘤中间变型的预后趋势需谨慎解读,其p值未达统计学显著。
局限性
- 间变型的预后意义基于五项临床试验队列,结论外推需谨慎。
- TP53突变与间变型的关系为探索性发现,尚未确立其预后价值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Established prognostic indicators in rhabdomyosarcoma (RMS), the most common childhood soft tissue sarcoma, include several clinicopathologic features. Among pathologic features, anaplasia has been suggested as a potential prognostic indicator, but the clinical significance of anaplasia remains unclear. METHODS: Patients enrolled on one of five recent Children's Oncology Group clinical trials for RMS (D9602, n = 357; D9802, n = 80; D9803, n = 462; ARST0331, n = 335; and ARST0531, n = 414) with prospective central pathology review were included in this study. Clinicopathologic variables including demographic information, risk group, histologic subtype, and anaplasia were recorded along with overall survival (OS) and failure-free survival (FFS) with failure defined by recurrence, progression, or death. The log-rank test was used to compare OS and FFS. RESULTS: Anaplasia was more common in embryonal RMS (27% of all embryonal RMS) than other subtypes of RMS (11% for alveolar RMS, 7% for botryoid RMS, 11% for spindle cell RMS). On multivariate analyses, anaplasia was not an independent prognostic factor in RMS (OS:hazard ratio (HR) = 1.12, p = 0.43; FFS:HR = 1.07, p = 0.56) across all subtypes or within embryonal RMS only (OS:HR = 1.41, p = 0.078; FFS:HR = 1.25, p = 0.16). Among tumors with TP53 mutations, 69% had anaplasia, while only 24% of tumors with anaplasia had a tumoral TP53 mutation. CONCLUSIONS: Anaplasia is not an independent indicator of adverse outcomes in RMS. Emerging information on the prognostic significance of TP53 mutations raises the possibility that anaplasia may be a surrogate marker of TP53 mutations in some cases. Tumoral TP53 mutation status may be investigated as a prognostic indicator in future studies.
引用
- Shenoy A, Alvarez E, Chi YY, et al. The prognostic significance of anaplasia in childhood rhabdomyosarcoma: A report from the Children's Oncology Group. Eur J Cancer. 2020. PMID: 33302115. doi:10.1016/j.ejca.2020.10.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。